RxDoctor Payments Data

Zeid Khitan, MD

Nephrology · Huntington, WVNPI 1881659555

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.4% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by AstraZeneca at 40.3% of the total. That places this record below the midpoint for nephrology clinicians in WV, where the typical reported total is $740.

$529in general payments, 2019–2025

Across 13 payments — averaging $40.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$214
  • Calliditas Therapeutics US Inc.$125
  • Mallinckrodt Hospital Products Inc.$78
  • Ardelyx, Inc.$56
  • Vifor Pharma, Inc.$24
  • Otsuka America Pharmaceutical, Inc.$18
  • plus $16 from 1 others
$722in research payments, 2019–2025

Across 1 payment — averaging $722.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$722

What the payments were for

  • Food & beverage$50595%
  • Education$245%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$529 in reported general payments places this provider in the 40th percentile of 55 nephrology providers in West Virginia.

See all nephrology providers in West Virginia

Medicare billing

Part B allowed, 2024
$322,601
Medicare patients
593
Services billed
3,261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin83$90,619
VelphoroSucroferric Oxyhydroxide27$59,272
Potassium Citrate ErPotassium Citrate24$3,013
Sevelamer Carbonate31$2,732
Calcitriol105$1,753
Spironolactone175$1,505
Torsemide79$1,357
Losartan Potassium177$1,248
Chlorthalidone63$887
Nifedipine ErNifedipine23$854
Potassium Chloride47$744
Furosemide131$677
Allopurinol55$675
Lisinopril107$608
Amlodipine Besylate110$583

Paid to pharmacies, not to this prescriber.

Other nephrology in Huntington

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →